Altered regulation of mitogen-activated protein kinases and GLUT4 expression in skeletal muscle, liver, heart and kidney of obese Zucker rat by Kundla, Sudarsanam
Marshall University
Marshall Digital Scholar
Theses, Dissertations and Capstones
1-1-2011
Altered regulation of mitogen-activated protein
kinases and GLUT4 expression in skeletal muscle,
liver, heart and kidney of obese Zucker rat
Sudarsanam Kundla
kundla@marshall.edu
Follow this and additional works at: http://mds.marshall.edu/etd
Part of the Systems and Integrative Physiology Commons
This Thesis is brought to you for free and open access by Marshall Digital Scholar. It has been accepted for inclusion in Theses, Dissertations and
Capstones by an authorized administrator of Marshall Digital Scholar. For more information, please contact zhangj@marshall.edu.
Recommended Citation
Kundla, Sudarsanam, "Altered regulation of mitogen-activated protein kinases and GLUT4 expression in skeletal muscle, liver, heart
and kidney of obese Zucker rat" (2011). Theses, Dissertations and Capstones. Paper 49.
 
 
Altered regulation of mitogen-activated protein kinases and GLUT4 expression in skeletal 
muscle, liver, heart and kidney of Obese Zucker rat 
A thesis submitted to the 
Graduate College of Marshall University 
In partial fulfillment of the requirements for the degree of 
Master of Science 
Department of Biological Sciences 
By 
Sudarsanam Kundla 
 
Approved by 
 
                                           Dr. Eric R. Blough, Committee Chairperson 
                                           Dr. Simon Collier, Committee Member 
                                           Dr. David S. Mallory, Committee member 
 
Marshall University 
Huntington, West Virginia 
December 2011 
 
 
 
 
 
ii 
 
ACKNOWLEDGMENTS 
 
It is of immense pleasure to thank my mentor and guide Dr. Eric R. Blough for supporting 
me throughout my master’s degree and without whose support I wouldn’t have completed this 
thesis. Dr. Blough has been supportive and helpful throughout my master’s program and I am 
blessed to have a wonderful guide like him. With his enthusiasm, inspiration, and great efforts to 
explain things clearly and simply, he made research very interesting to me. Throughout my thesis-
writing period, he provided encouragement, sound advice, good teaching, and lots of good ideas. I 
would have been lost without him. I would also like to thank my committee member Dr. Simon 
Collier whose valuable suggestions and comments helped me in completing my thesis. I also 
would like to thank Dr. David S. Mallory for his valuable thoughts about the research work and 
comments on the thesis work. Last but not the least I would like to extend my heartfelt thanks to 
my lab members and colleagues Sunil, Kevin, Anjaiah, Miaozong, Thulluri, Arvapalli, Madhukar, 
Hari, Siva, Paturi, Para, Prasanna, Geeta, Sravanthi and Eli. Lastly, and most importantly, I wish to 
thank my parents K.V.Ramanaiah, Adilakshmi, my wife and kids for all the support and 
encouragement they have given me. 
 
 
 
 
 
 
 
 
iii 
 
                                                              Table of Contents 
 
ACKNOWLEDGMENTS................................................................................................................................ii 
ABBREVIATIONS ......................................................................................................................................... v 
LIST OF FIGURES .......................................................................................................................................vii 
ABSTRACT ................................................................................................................................................. viii 
CHAPTER 1 .................................................................................................................................................... 1 
Introduction .................................................................................................................................................. 1 
Purpose ......................................................................................................................................................... 2 
Specific Aim #1 ........................................................................................................................................... 3 
To determine if the expression of total and phosphorylated levels of Akt, MAPK family, MEF2, 
GLUT4 pathway related proteins and mir-1,133a, 223 miRNA are altered in the skeletal and cardiac 
muscles of lean and obese Zucker rats with type 2 diabetes. ................................................................... 3 
Specific Aim #2 ........................................................................................................................................... 4 
To determine if the expression of total and phosphorylated levels of Akt, MAPK family, MEF2, 
GLUT4 pathway related proteins and mir-223 miRNA are altered in the liver of lean and obese Zucker 
rats with type 2 diabetes. .......................................................................................................................... 4 
Specific Aim #3 ........................................................................................................................................... 4 
To determine if the expression of total and phosphorylated level of Akt, MAPK family, MEF2, 
GLUT4 pathway proteins are altered in the kidney of lean and obese Zucker rats with type 2 diabetes. 4 
Review of Literature .................................................................................................................................... 5 
Introduction .............................................................................................................................................. 5 
Type 1 and Type 2 diabetes ..................................................................................................................... 5 
Summary .................................................................................................................................................. 6 
Models of metabolic syndrome ................................................................................................................ 7 
Summary .................................................................................................................................................. 9 
Summary ................................................................................................................................................ 12 
CHAPTER 3 .................................................................................................................................................. 15 
ABSTRACT ................................................................................................................................................... 16 
Introduction ................................................................................................................................................ 17 
Materials and methods ............................................................................................................................... 18 
Animal care ............................................................................................................................................ 18 
Tissue collection..................................................................................................................................... 19 
Tissue homogenization and determination of protein concentration ..................................................... 19 
iv 
 
SDS-PAGE and immunoblotting ........................................................................................................... 19 
RNA extraction and miRNA analysis .................................................................................................... 20 
Statistical analysis ...................................................................................................................................... 22 
Results ........................................................................................................................................................ 22 
Insulin resistance decreases muscle and liver GLUT4 levels. ............................................................... 22 
Insulin resistance decreases the amount of Akt phosphorylation in skeletal muscle and liver. ............. 22 
Insulin resistance affects the phosphorylation of MAPK proteins ......................................................... 23 
Insulin resistance is associated with alterations in miRNA expression ................................................. 23 
Discussion .................................................................................................................................................. 24 
CHAPTER 4 .................................................................................................................................................. 28 
Conclusions ............................................................................................................................................ 28 
Future Directions .................................................................................................................................... 29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
ABBREVIATIONS 
  
BSA  Bovine serum albumin 
CDC       Center for Disease Control and Prevention 
DM  Diabetes mellitus 
ECL  Enhanced chemiluminiscence 
PI-3 Kinase                 Phosphoinositide 3-kinase 
ERK1/2  Extra signal regulatory kinase 
GLUT 4  Glucose transporter type 4 
JNK  c-Jun N-terminal kinase 
LH  Lean Zucker heart 
LK  Lean Zucker kidney 
LL  Lean Zucker liver 
LM  Lean Zucker skeletal muscle 
MAPK  Mitogen activated protein kinase 
MEF2  Myocyte enhancement factor-2 
NIH                             National Institute of Health 
OH  Obese Zucker heart 
OK  Obese Zucker kidney 
OL  Obese Zucker Liver 
OM   Obese Zucker skeletal muscle 
PKB  Protein kinase B 
SEM  Standard Error of Mean 
SDS-PAGE  Sodium dodecyl Sulfate-polyacrylamide gel electrophoresis 
vi 
 
TBS  Tris buffered saline 
TBST  Tris buffered saline with 0.5% tween 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
LIST OF FIGURES 
 
Figure 1. Pictorial representation of activation and translocation of GLUT4 via MAPK ............... 13 
Figure 2. Schematic representation of MAPK mediated GLUT4 regulation .................................. 14 
Figure 3. Total levels of GLUT4 are altered in diabetic rats ........................................................... 30 
Figure 4. Phosphorylated to total levels of Akt are altered in diabetic rats. .................................... 31 
Figure 5. Phosphorylated to total levels of p38MAPK are altered in diabetic rats. ........................ 32 
Figure 6. Phosphorylated to total levels of PTEN are altered in diabetic rats. ................................ 33 
Figure 7. Phosphorylated to total levels of ERK1/2 are altered in diabetic rats. ............................. 34 
Figure 8. Phosphorylated to total levels of JNK are altered in diabetic rats. ................................... 35 
Figure 9. Total levels of MEF2A are altered in diabetic rats........................................................... 36 
Figure 10. The expression of mir-1 miRNA is altered in diabetic rats. ........................................... 37 
Figure 11. The expression of mir-133a miRNA is altered in diabetic rats. ..................................... 38 
Figure 12. The expression of mir-233 miRNA is altered in diabetic rats. ....................................... 39 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
ABSTRACT 
Background: Metabolic syndrome is characterized by insulin resistance and hyperglycemia. The 
molecular mechanism(s) underlying this alteration in skeletal muscle, liver, kidneys and heart in 
metabolic syndrome patients are presently unclear. Recent data have demonstrated that the p38 
and extracellular-signal-regulated kinases (ERK 1/2) - mitogen-activated protein kinase (MAPK) 
proteins may be involved in the regulation of (Glucose transporter type 4) GLUT4 expression 
levels. Other data have suggested that miRNA may also play a role. Purpose: The purpose of this 
study is to compare the tissue content, phosphorylation of protein kinases (AKT), p38, c-JUN N-
terminal kinase(JNK), ERK1/2, GLUT4 and transcriptional factor Myocyte enhancer factor-2 
(MEF2) in the skeletal muscle, heart, liver and kidney of insulin resistant obese (fa/fa) and lean 
Zucker rats. Methods: Skeletal muscle, heart, liver and kidney were obtained from obese (n=6) 
and lean (n=6) Zucker rats. The amount and phosphorylation status of AKT, p38, JNK, ERK 1/2, 
GLUT4 and MEF2 were evaluated by immunoblotting. Results: Decreased GLUT4 expression 
levels were observed in the skeletal muscle, liver and heart of obese Zucker rats compared to lean 
zucker rats and are associated with alterations in the phosphorylation of MAPK family members. 
Levels of mir-1and 133a were altered in skeletal and cardiac muscles of obese Zucker rats when 
compared with their lean counterparts. Conclusions: These results suggest that MAPK members 
regulate GLUT4 expression differently in various insulin resistant tissues compared to lean 
counterparts and that these changes may play a key role in insulin resistance associated with 
glucose dysregulation.  
Key words: Insulin resistance, Akt, P38, Erk1/2, JNK, MEF2, GLUT4 
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CHAPTER 1 
 
Introduction 
 According to the World Health Organization diabetes fact sheet for January 2011 
approximately 220 million people worldwide have diabetes and it is estimated that this will rise 
to 366 million by 2030.  The Centers for Disease Control and Prevention has estimated that 
about 8.3 percent of the total United States populations are diabetic. Diabetes mellitus (DM) is a 
serious, life-threatening condition that is characterized by high levels of blood glucose resulting 
from defects in insulin production, insulin action, or both [1]. Individuals with type 2 diabetes 
typically exhibit characteristics of metabolic syndrome and insulin resistance characterized by 
hyperinsulinemia, hyperlipidemia and hyperglycemia [2]. The obese Zucker (fa/fa) rats are leptin 
deficient models that result in an early onset of type 2 diabetes and exhibit the characteristics of 
metabolic syndrome and are therefore thought to be an appropriate model for diabetes related 
studies. 
Metabolic syndrome is associated with alterations in insulin signaling that can lead to 
insulin resistance and hyperglycemia [3]. Insulin resistance is the cause of type 2 diabetes thatis 
linked with several other factors and plays a key role in pathogenesis of metabolic syndrome [3]. 
A key regulator of insulin induced glucose uptake is the glucose transporter (GLUT4) [4].  It is 
thought that the GLUT4 is regulated, at least in part, by PI3K that, when phosphorylated causes 
recruitment of protein kinase B (PKB) and PDK1 [5]. There is overwhelming evidence to 
support the role of Akt/PKB in insulin stimulated glucose uptake [6-8]. Mitogen activated 
protein kinases are also thought to play a role in the GLUT4 expression and relocation. The 
stress-responsive kinase, p38 mitogen-activated protein kinase (p38-MAPK), ERK1/2 (extra 
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signal regulatory kinases) have been found to be involved in the regulation of GLUT4 expression 
by activating the transcription factor MEF2 that, in turn, activates the GLUT4 promoter [9].  
Though it is well established that insulin resistance is associated with glucose dysregulation, 
whether differences exist between normal and insulin resistant tissues in the regulation of MAPK 
members and GLUT4 levels remains unclear. To our knowledge, the mechanism of insulin 
signaling in different sensitive tissues like skeletal muscle, liver, heart and kidney of normal and 
diabetic animal has not been investigated. 
 
Purpose 
Our long-term goal is to elucidate the organ specific differences in insulin induced 
signaling in lean and obese Zucker rats that could provide vital information in further 
understanding the molecular mechanisms and drug targets of insulin resistance. The objective of 
this study is to determine whether insulin resistance alters insulin related signaling mechanisms 
differently in skeletal muscle, liver, kidneys and heart. To achieve the objective we will  compare 
the tissue content of phosphorylated levels of AKT, p38 mitogen activated protein kinases, JNK 
(c-Jun N-terminal kinases), ERK1/2 (extracellular regulatory kinases), GLUT4 (glucose 
transporter) and transcriptional factor Myocyte enhancer factor-2 (MEF2) in the skeletal muscle, 
heart, liver and kidney of Obese (fa/fa) and Lean Zucker rats.  We will also investigate the role 
of different microrna in regulation of GLUT4 expression in type 2 diabetes that might be useful 
in designing therapeutic targets. 
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Specific Aims 
Estimated global healthcare expenditures to treat and prevent diabetes and its 
complications are expected to total US Dollar (USD) 376 billion in 2010. By 2030, this number 
is projected to exceed some USD 490 billion (International diabetes federation, diabetes atlas). 
Diabetes is the sixth leading cause of death in the US. The economic burden posed by diabetes is 
daunting with the total cost of diabetes in the U.S. in 2007 at an estimated 174 billion and this 
cost is estimated to almost triple in the next 25 years (American Diabetes Association). As such, 
it is clear that the scientific community must continue to search for the most effective methods 
for the treatment and prevention of this disease. Recent data have suggested that the p38 and 
extracellular-signal-regulated kinases (ERK 1/2)-mitogen-activated protein kinase (MAPK) 
proteins may be involved in the regulation of (Glucose transporter type 4) GLUT4 expression 
levels. As of yet no concrete study has been done to indicate whether differences exist in insulin 
signaling in different insulin resistant tissues. The working hypothesis of this study is that 
differences exist between normal and diabetic skeletal muscle, heart, liver, kidney in the insulin 
signaling pathway. To test this hypothesis and accomplish the purpose of this study the following 
specific aims are proposed: 
   
Specific Aim #1 
To determine if the expression of total and phosphorylated levels of Akt, MAPK family, 
MEF2, GLUT4 pathway related proteins and mir-1,133a, 223 miRNA are altered in the skeletal 
and cardiac muscles of lean and obese Zucker rats with type 2 diabetes. 
Hypothesis: 
Type 2 diabetes will be associated with alterations in the expression of total and 
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Phosphorylated level of Akt, MAPK family, MEF2, GLUT4 pathway related proteins and 
mir-1,133a, 223 miRNA in the skeletal and cardiac muscles of lean and obese Zucker 
rats. 
 
Specific Aim #2 
  To determine if the expression of total and phosphorylated levels of Akt, MAPK family, 
MEF2, GLUT4 pathway related proteins and mir-223 miRNA are altered in the liver of lean and 
obese Zucker rats with type 2 diabetes. 
 
Hypothesis: 
Type 2 diabetes will be associated with alterations in the expression of total and 
Phosphorylated levels of Akt, MAPK family, MEF2, GLUT4 pathway related proteins 
and mir-223 miRNA in the liver of lean and obese Zucker rats. 
 
Specific Aim #3 
To determine if the expression of total and phosphorylated level of Akt, MAPK family, 
MEF2, GLUT4 pathway proteins are altered in the kidney of lean and obese Zucker rats with 
type 2 diabetes. 
 
Hypothesis: 
Type 2 diabetes will be associated with alterations in the expression of total and 
Phosphorylated levels of Akt, MAPK family, MEF2, GLUT4 pathway proteins in the 
kidney of lean and obese Zucker rats 
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                                                                  CHAPTER 2 
 
                                                             Review of Literature 
Introduction 
A review of the literature pertaining to this study will be discussed here in this chapter in 
detail. The following topics that are aptly related will be addressed: 1) Type 1 and Type 2 
diabetes, 2) models of metabolic syndrome, and 3) regulation of glucose uptake in different 
insulin sensitive tissues. 
 
Type 1 and Type 2 diabetes 
 Diabetes mellitus (DM) is an emerging epidemic in United States and the world over that, 
if allowed to proceed unchecked, can progress into a deadly metabolic syndrome affecting 
almost all the vital organs in the body. Diabetes mellitus can be described as the uncontrolled 
regulation of circulating glucose levels that is oftentimes dues to a failure in insulin production 
or unresponsiveness of the tissues to insulin stimulation [10]. According to the World Health 
Organization, approximately 3.4 million people died from consequences of high blood sugar in 
2004. It is currently estimated that 346 million people suffer from diabetes worldwide. Here in 
the United States, the American Diabetes Association has estimated that the total number of 
people with diabetes in 2011 will be approximately 25.8 million, or 8.3% of the total population. 
It is also estimated that the number of people exhibiting pre-diabetes in the United States will be 
79 million by the end of 2011. 
 Type 1 diabetes mellitus is characterized by failure of pancreatic islets of Langerhans to 
produce adequate amounts of insulin. Type 1 diabetes mellitus is an autoimmune mediated 
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disease that occurs in 1 of every 300 individuals in United States although it may sometimes be 
due to idiopathic nature [11]. Type I diabetes is commonly diagnosed in children and hence 
commonly referred to as juvenile onset diabetes or insulin dependent diabetes mellitus. This 
disorder represents about five to ten percent of all recorded diabetic cases. Currently there is no 
cure for type I diabetes [12]. 
 Type 2 diabetes mellitus is characterized by insulin resistance where the responsiveness 
of the target tissues to circulating levels of insulin is decreased [13]. In Type 2 diabetes there is a 
gradual change from normal glucose tolerance to abnormal glucose tolerance. This shift in 
tolerance is characterized at first by an increase in postprandial glucose levels that gradually 
increases to hyperglycemia [14]. Previous studies have shown that genetics, obesity, physical 
inactivity and environmental factors pose as risk factors for development of Type 2 diabetes 
[15]. Recent studies have demonstrated that insulin resistance is associated with changes in 
GLUT4 expression and alterations in insulin receptor isoform expression and IGF-I receptor 
abundance [16, 17]. Other work has suggested that that impaired phosphorylation of IRS-1 
receptor and reduced PI3Kinase activity may also play a role in mediating insulin resistance in 
skeletal muscle [18]. Whether a similar mechanism is present in other tissue types has, to our 
knowledge, not been investigated.  
 
Summary 
 Type I diabetes mellitus is primarily due to an autoimmune disease in which the beta 
cells of the pancreas are destroyed leading to diminished insulin production. Type I diabetes 
comprises of about five to ten percent of all diabetic cases whereas Type II diabetes comprises 
about ninety to ninety five percent. Type II diabetes mellitus occurs primarily due to a failure of 
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cells to respond to insulin. Although the exact mechanism(s) are currently unclear, Type 2 
appears to be associated with changes in receptor isoforms and the propagation of intracellular 
signaling. 
 
Models of metabolic syndrome 
 A suitable experimental model is a prerequisite for the success of any scientific study. 
The selection of model depends primarily on the study and its potential applications. Research 
centered toward diabetes has widely used rodent models for study due to their short life span and 
the ability to control the external environment.  
 There are several strains of rodents for diabetic research such as Goto-Kakizaki rat, non-
obese diabetic rats, Nagoya-Shibata-Yasuda mouse, Pound mouse, obese Zucker rats and others 
[19]. The selection of particular model among these is typically dependent upon the type of 
diabetes being investigated and the dependent variables that are being measured. For example the 
Non-Obese Diabetic (NOD/NHsd) rats serve as a model for research in Type 1 diabetes mellitus 
as they develop insulitis due to leukocytic infiltration of pancreatic islets [20]. In addition, the 
onset of diabetes in these rats is associated with glycosuria and non-fasting hyperglycemia.  The 
Goto-Kakizaki (GK) rat is a non-obese Wistar sub strain which develops Type 2 diabetes and 
exhibits hyperinsulinemia, insulin resistance, neuropathy, retinopathy and nephropathy [21].  
Similarly, the Nagoya-Shibata-Yasuda mouse develops spontaneous non-insulin-dependent 
diabetes. This model is particularly suitable for studying the genetics of diabetes [22]. In 
addition, this strain also exhibits some characteristics of diabetes seen in humans including 
impaired insulin secretion, visceral fat accumulation and the ability to induce development of 
this disease by dietary manipulation. Another model for type 2 diabetic is the Israel Sand rat or 
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Psammomys obesus, which belongs to the gerbil family [23]. These rats exhibit impaired insulin 
sensitivity accompanied by increased adiposity before the onset of insulin resistance in a manner 
that closely resembles human type 2 diabetes [23]. Another strain that has also been developed is 
the  Pound mouse (C57BL/6NCrl-Lepr
db-db
/Crl), which exhibits hyperinsulinemia, insulin 
resistance, dyslipidemia, metabolic syndrome, leptin deficiency and fatty liver disease [24]. This 
strain develops hyperinsulinemia by 8 weeks of age with insulin levels exceeding 300 ng / ml by 
18 weeks.  
 
Obese Zucker rat model  
The most commonly and perhaps best suited model for type 2 diabetes study is the obese 
Zucker rat that was developed through selective breeding over many generations. These animals 
exhibit hyperinsulinemia, hyperphagia, hypercholesterolemia and hyperglycemia along with 
central obesity[25]. These animals are also considered to be excellent models for the study of 
metabolic syndrome as they also exhibit glucose intolerance, insulin resistance, increased 
oxidative stress in heart and liver, borderline hypertension, cardiac hypertrophy and increased 
mean arterial pressure [25-27]. Other characteristics include increased hepatic glycogen, 
impaired glycogen synthesis, steatosis and proteinuria, peripheral neuropathy and altered 
sympathetic and parasympathetic activity [28]. Taken together, these data suggest that the obese 
Zucker is highly suited for the study of Type 2 diabetes and metabolic syndrome.  
 Earlier studies on the hearts of obese Zucker rats demonstrated that the hyper- 
phosphorylation of IRS-1 may significantly contribute to pathogenesis of insulin resistance in the 
heart [29]. They also correlated the alterations in insulin-induced glucose transport activation and 
GLUT4 translocation to possible defects of the insulin signaling cascade [29]. Carvalho et al.,   
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demonstrated that insulin resistance in the adipocytes of obese Zucker rats is characterized by 
impaired glucose transporter 4 (GLUT4) translocation and diminished GLUT4 expression due to 
signaling defects associated with reductions in protein kinase B (AKT) and PI3K activation [30].  
 
Summary 
 Millions of Americans have been diagnosed with type 2 diabetes, and many more are 
unaware that they are at high risk. The obese Zucker (fa/fa) rat appears to be an appropriate 
animal model for studying diabetes given its phenotypic properties and the similarities to that 
seen in humans. Few studies have investigated molecular mechanisms that are responsible for 
insulin resistant in the obese Zucker rat model. Elucidating the molecular events responsible for 
insulin resistance may be beneficial designing pharmacological interventions for the treatment of 
this disease. 
 
Regulation of glucose uptake in different vital organs 
 A major metabolic defect associated with type 2 diabetes is the failure of tissues in the 
body to properly utilize glucose, thereby resulting in chronic hyperglycemia. Given that 
elevations in blood glucose levels can be toxic, it is of importance to understand the underlying 
molecular mechanisms that regulate insulin resistance. In the early 1980s, Dr. Cushman and 
colleagues proposed a novel mechanism in which vesicles containing glucose transporters could 
be mobilized to the plasma membrane by insulin stimulation , thereby effecting glucose transport 
into the cell [31]. Subsequent studies have largely confirmed this initial work and have begun to 
unravel the signaling mechanisms responsible for regulating glucose transporter movement to the 
cell membrane.  
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A key regulator of insulin-induced glucose uptake is the glucose transporter (GLUT4). 
GLUT4 is primarily expressed in skeletal muscle and adipocytes. Under conditions of low 
insulin, GLUT4 is sequestered in intracellular vesicles. Conversely, when insulin levels are 
increased, translocation of GLUT4 transporters occurs. This process appears to be initiated by 
insulin binding to the insulin receptor that then activates the receptor's tyrosine-kinase domain. 
The receptor, now activated, in turn phosphorylates the insulin receptor substrate-1 (IRS-1) that, 
in turn, binds the enzyme PI-3 kinase. PI-3 kinase then activates protein kinase B (AKT) through 
its phosphorylation. Activation of AKT through an as of yet underdetermined mechanism, then 
induces the movement of GLUT4 containing vesicles from the cytoplasm to the plasma 
membrane. 
 
Intracellular signaling pathways that regulate GLUT4 activity and expression 
The mitogen-activated protein kinases (MAPK) are serine/threonine-specific protein 
kinases that respond to extracellular stimuli. The MAPK proteins, when activated function to 
regulate various cellular activities including gene expression, differentiation, proliferation, and 
cell survival or apoptosis [32]. The p38-MAPK is a mammalian orthologue of the yeast Hog1p 
MAP kinase, which participates in a signaling cascade controlling cellular responses to cytokines 
and stress. There are four different isoforms of p38 MAPK: α, β, γ and δ. Previous studies have 
shown that hyperglycemia can activate p38 kinase in a protein kinase C (PKC) - δ isoform-
dependent manner [33]. Michelle et al., in 2003 proposed a model in which GLUT4 
translocation by insulin was dependent upon both AKT/PKB and p38 MAPK activation [34].  
Other data have shown that extremely elevated levels of glucose can also activate p38 kinase in a 
PKC-independent manner, most likely by inducing hyperosmolarity [33].  
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The extracellular signal regulated kinases (ERKs) are members of the MAPK family, 
which are involved in regulation of meiosis, mitosis, and in modulating gene expression. The 
ERK-MAPK proteins are activated by a variety of stimuli such as growth factors, cytokines, and 
carcinogens. Jing et al. showed that fatty acids can cause an increase in glucose uptake by 
activation of ERK1/2.  
 In addition to the PI-3K, Akt and the MAPK proteins, the myocyte enhancer factor-2 
transcription factor may also play a role in regulating glucose uptake through its ability to 
regulate GLTU-4 protein expression. The myocyte enhancer factor-2 (MEF2) proteins are a 
family of transcription factors, which control gene expression and regulate cellular 
differentiation and development during the embryonic development. In adults, MEF2 is involved 
in regulation of various stress responses. Thus far, four isoforms of MEF2 have been delineated: 
MEF2A, MEF2B, MEF2C and MEF2D. It has been shown that p38 MAPK can phosphorylates 
MEF2, ATF-2, and MAX transcription factors under different conditions. Previous studies have 
shown that MEF2 protein regulates cardiac hypertrophy and tissue remodeling in skeletal muscle 
in response to stress [35, 36] . Mora et al., demonstrated that cardiac and skeletal muscle 
expression of GLUT4 is dependent upon a MEF2A-MEF2D heterodimer [37]. Recently, 
Christophe et al., showed that activation of p38 MAPK caused an increase in the expression of 
GLUT4 in response to IGF-1 in cardiac myocyte. In addition, this group also showed that MEF2 
was the main transcription factor transducing the effect of p38 MAPK activation on the GLUT4 
promoter [9]. Whether the mechanisms regulating the expression and activation of GLUT4 
expression differ in different organs is not clear. Elucidating the molecular events responsible for 
alterations in GLUT4 expression in different organs of no diabetic and diabetic animals may be 
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beneficial for the development of new pharmacological interventions to treatment this Type 2 
diabetes. 
 
 
MicroRNAs 
 MicroRNAs are short ribonucleic acid molecules that act as post-transcriptional 
regulators by binding to complementary sequences on target messenger RNA transcripts. This 
binding, in turn, results in translational repression or target degradation. Elia et al., showed that 
miR-1 controls the expression of insulin-like growth factor-1  and IGF-1 receptor protein levels 
by translation in a reciprocal relationship [38]. Fred et al., showed that high glucose suppresses 
human Islet insulin biosynthesis by inducing miR-133a [39]. Recently Lu et al., provided 
interesting evidence with regards to regulation of glucose uptake by mir-223. They found that 
over expression of miR-223 resulted in an increase in expression of glucose transporter4 (Glut4) 
protein without effecting PI3Kinase or AMP Kinase activity [40]. Whether similar findings are 
observed in vivo is currently unclear.  
 
Summary 
 Type 2 diabetes is characterized by unresponsiveness of the cells to normal levels of 
circulating insulin. GLUT4 is a primary glucose transporter protein for skeletal and cardiac 
muscle. Under elevated glucose conditions, GLUT4 is translocated to plasma membrane where it 
is responsible for up taking glucose into the cell. The regulation of GLUT4 function and 
expression appears to be mediated by the activity of the PI3K, Akt and MAPK signaling 
systems. The MEF2A transcription factor is activated by the MAPK pathways by high glucose 
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levels and may participate in the regulation of GLUT4 expression levels. Recent data suggest 
that miRNA may also play a role in regulating GLUT4 expression. It is currently unclear if the 
regulation of GLUT4 translocation and expression is regulated similarly in different tissue types.  
 
Figure 1. Pictorial representation of activation and translocation of GLUT4 via MAPK            
                 family 
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Figure 2. Schematic representation of MAPK mediated GLUT4 regulation 
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Altered regulation of Mitogen-activated protein kinase (MAPK) mediated GLUT4 
expression in skeletal muscle, liver, heart and kidney of Obese Zucker rat 
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ABSTRACT 
Background: Metabolic syndrome is characterized by insulin resistance and hyperglycemia. The 
molecular mechanism(s) underlying this alteration in skeletal muscle, liver, kidneys and heart in 
metabolic syndrome patients are presently unclear. Recent data have demonstrated that the p38 
and extracellular-signal-regulated kinases (ERK 1/2) - mitogen-activated protein kinase (MAPK) 
proteins may be involved in the regulation of (Glucose transporter type 4) GLUT4 expression 
levels. Other data have suggested that miRNA may also play a role. Purpose: The purpose of 
this study is to compare the tissue content, phosphorylation of protein kinases (AKT), p38, c-
JUN N-terminal kinase(JNK), ERK1/2, GLUT4 and transcriptional factor Myocyte enhancer 
factor-2 (MEF2) in the skeletal muscle, heart, liver and kidney of insulin resistant obese (fa/fa) 
and lean Zucker rats. Methods: Skeletal muscle, heart, liver and kidney were obtained from 
obese (n=6) and lean (n=6) Zucker rats. The amount and phosphorylation status of AKT, p38, 
JNK, ERK 1/2, GLUT4 and MEF2 were evaluated by immunoblotting. Results: Decreased 
GLUT4 expression levels were observed in the skeletal muscle, liver and heart of obese Zucker 
rats compared to lean zucker rats and are associated with alterations in the phosphorylation of 
MAPK family members. Levels of mir-1and 133a were altered in skeletal and cardiac muscles of 
obese zucker rats when compared with their lean counterparts. Conclusions: These results 
suggest that MAPK members regulate GLUT4 expression differently in various insulin resistant 
tissues compared to lean counterparts and that these changes may play a key role in insulin 
resistance associated with glucose dysregulation.  
Key words: Insulin resistance, Akt, P38, Erk1/2, JNK, MEF2, GLUT4 
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Introduction 
The Centers for Disease Control and Prevention estimates that nearly 26 million 
Americans or about 8% of the total population are diabetic [10]. Diabetes remains the sixth 
leading cause of death in the United States and costs $174 billion annually, including $116 
billion in direct medical expenses. Perhaps most worrisome is the fact that an additional 35% of 
all adults are considered pre-diabetic.  
Type 2 diabetes accounts for about 90-95% of all diabetes cases and is thought to be 
caused, at least in part, by insulin resistance [3]. The regulation of glucose uptake into the cell in 
response to elevations in extracellular insulin is not fully understood. A key regulator of insulin-
induced glucose uptake is the glucose transporter (GLUT4) [4]. GLUT4 redistributes from the 
intracellular membrane pool to plasma membrane upon insulin stimulation [41]. Activation of 
insulin receptor by insulin is thought to stimulate the PI3-kinase pathway. The PI3-kinase, in 
turn, recruits the serine/threonine protein kinases protein kinase B (PKB or Akt) and PDK1 [5], 
which results in the stimulation of glucose uptake [6-8]. In addition to Akt, the mitogen activated 
protein kinases (MAPK) are also thought to play a role in the GLUT4 expression and relocation. 
The p38-MAPK has been found to be involved in the regulation of GLUT4 expression by 
activating the transcription factor MEF2, which functions to activate the GLUT4 promoter [9]. 
Besides p38-MAPK, regulation of glucose uptake has also been found to be influenced by the 
extracellular-regulated kinase 1/2 (ERK1/2)–MAPK as the phosphorylation of this molecule is 
thought to be involved in regulating insulin receptor signaling and GLUT4 translocation [42-
44]. Conversely, the activation of c-Jun N-terminal Kinase (JNK) has been found to be impair 
the insulin-signaling pathway by serine phosphorylation of IRS proteins [45]. How insulin 
18 
 
regulated signaling and GLUT4 expression is regulated in different tissues is to our knowledge, 
not been investigated.  
The purpose of this study was to determine whether insulin resistance alters insulin 
related signaling mechanisms differently in skeletal muscle, liver, kidney and heart. To 
accomplish this goal, we examined the regulation of Akt, MAPK proteins, MEF2A and GLUT4 
in normal and insulin resistant obese Zucker rats. Taken together, our findings suggest that 
insulin related signaling appears to be regulated differently in different insulin sensitive tissues.  
 
Materials and methods 
 Animal care 
All procedures were performed as outlined in the Guide for the Care and Use of 
Laboratory Animals as approved by the Council of the American Physiological Society and the 
institutional animal use review board of Marshall University. Young male Lean Zucker (LZ, n 
=6) and Obese Zucker (OZ, n =6) rats were obtained from the Charles River Laboratories. All 
animals were 12 weeks of age at completion of this study. Rats were housed two per cage in an 
American Association for the Accreditation of Laboratory Animal Care approved vivarium. 
Housing conditions consisted of a 12:12-h dark-light cycle, and temperature was maintained at 
22 ± 2°C. Animals were provided food and water ad libitum and allowed to recover from 
shipment for at least two weeks before experimentation. During this time, the animals were 
carefully observed and weighed weekly to ensure none exhibited signs of failure to thrive, such 
as precipitous weight loss, disinterest in the environment, or unexpected gait alterations. 
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Tissue collection 
Rats were anaesthetized with a ketamine-xylazine (4:1) cocktail (50 mg/kg i/p) and 
supplemented as necessary for reflexive response before tissue collections. The plantaris 
muscles, liver, kidney, heart were collected, trimmed of excess connective tissue, weighed and 
flash frozen in liquid nitrogen. Samples were stored at -80 °C until further analysis. 
 
Tissue homogenization and determination of protein concentration 
Muscles, liver, kidney, heart samples were homogenized in Pierce Tissue Protein 
Extraction Reagent (10 ml/g tissue; Rockford) that contained protease inhibitors (P8340; Sigma-
Aldrich, St. Louis, MO) and phosphatase inhibitors (P5726; Sigma-Aldrich). After incubation on 
ice for 30 min, the homogenate was collected by centrifuging at 12,000 g for 5 min at 4°C. The 
protein concentration of homogenates was determined via the Bradford method (Fisher 
Scientific, Rockford, IL). Homogenate samples were boiled in a Laemmli 2X sample buffer 
(Sigma-Aldrich) for 5 min. 
 
SDS-PAGE and immunoblotting 
Total protein from each sample (45µg) was separated on a 10% PAGEr Gold Precast gel 
(Lonza, Rockland, ME) and then transferred to a nitrocellulose membrane. Visual verification of 
transfer and equal protein loading among lanes were accomplished by Ponceau S staining of the 
membranes. For immunodetection, membranes were blocked for 1 h at room temperature in 
blocking buffer [5% nonfat dry milk in 20 mMTris-base, 150mM NaCl, and 0.05% Tween 20 
(TBS-T), pH 7.6], serially washed in TBS-T at room temperature, and then probed with 
antibodies for the detection of Akt (#9272), phospho-Akt (Ser473) (# 9271), PTEN (# 9552), 
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phospho-PTEN (Ser380/Thr382/383) (#9549), p38 MAPK (#9212), phospho p38 MAPK (# 
9211), P44/42 MAPK (ERK1/2) (#9102), phospho p44/42 MAPK (Thr202/Tyr204) (#9101), 
SAPK/JNK (#9252), phospho SAPK/JNK (Thr183/Tyr185), MEF2A (#9736), GLUT4 (#2299) 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (#2118) (Cell Signaling Technology 
,Beverly, MA). Membranes were incubated overnight at 4°C in primary antibody buffer (5% 
BSA in TBS-T, pH 7.6. Primary antibody diluted 1:1,000) followed by washing in TBS-T (5 min 
each), and incubation with horseradish peroxidase conjugated secondary antibody [anti-rabbit (# 
7074) or anti-mouse (#7076); Cell Signaling Technology, Danvers, MA] in blocking buffer for 1 
h. After removal of the secondary antibody, membranes were washed (3x5 min) in TBS-T, and 
protein bands were visualized on reaction with ECL reagent (Amersham ECL Western Blotting 
reagent RPN 2106; GE Healthcare Bio-Sciences, Piscataway, NJ). Target protein levels were 
quantified by Alpha Ease FC image analysis software (Alpha Innotech, San Leandro, CA) and 
normalized to GAPDH. 
 
RNA extraction and miRNA analysis 
Skeletal muscle, heart, kidney and liver of lean and obese Zucker rats are homogenized 
Individually, on ice in a TRI reagent (Ambion, Austin, TX) at a ratio of 1 mL of TRI reagent  
Per 100 mg of tissue. The homogenate was incubated for 5 minutes on ice to allow nucleoprotein 
complexes to completely dissociate, and centrifuged at 4°C for approximately for 15 mins at 
12,000 x g.  The supernatant was separated from the pellet and transferred to a 2 ml RNAse-free 
tube. A 200-µl aliquot of chloroform (Sigma-Aldrich, Inc., St. Louis, MO) was added to the 
supernatant.  The solution was mixed and incubated at room temperature for 10 mins, followed 
by centrifugation at 4°C for 15 mins at 12,000 x g. The aqueous phase of the solution was 
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collected and transferred to another tube.  A 500- µl aliquot of isopropanol (Sigma-Aldrich, Inc., 
St. Louis, MO) was added to the aqueous phase, followed by thorough mixing.  The resultant 
solution was incubated at room temperature for 10 mins, followed by centrifugation at 4 °C for 
10 minutes at 12,000 x g. The supernatant was then carefully removed without disturbing the 
pellet.  The RNA pellet was washed free of salts by centrifugation in 75% ethanol at 7500 x g for 
5 minutes.  The ethanol wash was carefully removed without disturbing the pellet, and the 
residual ethanol was evaporated at room temperature by speed vacuuming for 1 minute.  The 
RNA pellet was dissolved in 50 µl of RNAse free water and quantified at 260 nm using a 
NanoVue UV-Vis Spectrophotometer (GE Healthcare, Piscataway, NJ).  The integrity of the 
RNA from each sample was determined through use of RNA 6000 Nano Kit and an Agilent 2100 
Bio analyzer (both from Agilent Technologies, Santa Clara, CA). Two micrograms of RNA were 
reverse transcribed (RT) using the QuantiMiR RT kit (System Bioscience) according to standard 
methods (Systems Bioscience). Control RT reactions were done in which the RT enzyme was 
omitted. The control RT reactions were PCR amplified to ensure that DNA did not contaminate 
the RNA. Cyber green-based real-time qPCR was performed by using a 7500 Real-Time PCR 
system (Applied Bio systems, Foster City, CA) and gene-specific primers for the miRNA of 
interest designed according to the guidelines outlined in the QuantiMiR RT kit (System  
Bioscience). Melt analysis was used after each PCR run to ensure amplification of only a single 
product. All samples were normalized to an internal control housekeeping gene (U1 small 
nuclear RNA (snRNA)).  Relative fold changes in miRNA within each group and basal 
differences between groups were determined from the Ct values after normalization to their 
respective housekeeping genes using the 2
∆ct
 method. 
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Statistical analysis 
Results are presented as means ± SE. Data were analyzed using the Sigma Stat 3.5 
statistical program. The effects of insulin resistance on protein phosphorylation were analyzed 
using a t- test. Differences were considered Significant at P < 0.05. 
 
Results 
Insulin resistance decreases muscle and liver GLUT4 levels.  
           GLUT4 levels were 16-, 33- and 45% lower in the obese Zucker plantaris, liver and heart, 
respectively (P<0.05). Conversely, GLUT4 expression was 51% higher in the obese Zucker 
kidney (P<0.05) (Figure 1). 
 
Insulin resistance decreases the amount of Akt phosphorylation in skeletal muscle and 
liver.  
Compared to lean animals, the ratio of phosphorylated (Ser 473) to total Akt was 32% 
and 27% lower in the skeletal muscle and liver of the obese Zucker rats (P<0.05) (Figure 2). 
Conversely, the ratio of p-Akt to total Akt was 12 and 11% higher in the obese Zucker heart and 
kidney (P<0.05). Compared to that observed in the lean animals, the ratio of phosphorylated 
(Ser380/Thr382) to total PTEN were 19- and 10% higher in the plantaris and liver, respectively 
(P<0.05) (Figure 4). Compared to that seen in the lean animals, the ratio of p-PTEN to PTEN 
was 8- and 24% lower in the obese Zucker rat heart and kidney (P<0.05).  
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Insulin resistance affects the phosphorylation of MAPK proteins 
 
Compared to that observed in the lean Zucker animals, the ratio of phosphorylated p38 
(Thr180/Tyr 182) 21-, 122- and 19% higher in the obese Zucker skeletal muscle, liver and 
kidney, respectively (P<0.05) (Figure 3).  
Compared to that seen in the lean animals, the ratio of phosphorylated ERK1/2 
(Thr202/Tyr204) to total ERK1/2 levels were higher in skeletal muscle (46%) but 19- and 39% 
lower in the liver and heart of the obese Zucker rats (P<0.05) (Figure 5). Similar to what we 
observed for ERK1/2, the ratio of phosphorylated (Thr183/Tyr185) to total JNK was 29% higher 
in skeletal muscle (29%) and 19% lower in the hearts of the obese Zucker rats compared with 
their lean counterparts (P<0.05) (Figure 6). MEF2A protein levels were 17- and 19% lower in 
the muscle and hearts of obese Zucker rats (P<0.05) (Figure 7).  
 
Insulin resistance is associated with alterations in miRNA expression 
 
The relative expression of mir-1 was 63% lower in the hearts of the obese Zucker rat 
compared to that observed in the control animal (P<0.05) (figure 8) Conversely, mir-1 
expression was 218% higher in the insulin resistant muscle. The expression of mir-133a was 
lower in obese Zucker skeletal muscle (96%) (P<0.05) but 120% higher in the obese Zucker 
heart (120%) (Figure 9). Compared to lean animals, the relative expression of mir-223 was 88- 
and 93% lower in the skeletal and hearts of the obese Zucker animals (P<0.05). Conversely, mir-
223 expression was 250% higher in the liver of obese compared to lean Zucker animals (P<0.05) 
(Figure 10).  
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Discussion 
Insulin resistance is thought to be one of the primary causes of Type 2 diabetes [1]. Liver, 
skeletal muscle and fat are important insulin sensitive tissues that play a primary role in the 
regulation of blood glucose levels. Impaired insulin sensitivity can affect cellular metabolism 
and lead to an increased reliance on fatty acids for the production of energy. This response, while 
first adaptive, can led to increased secretion of inflammatory cytokines and a further decrease in 
the insulin sensitivity of other tissues [49, 50].  
  The primary finding of this investigation was that the mechanism of insulin resistance 
appears to be regulated differently in different tissue types. Specifically, we found that the 
amount of GLUT4 appeared to be lower in the muscle, heart and liver but not in the kidney of 
the obese Zucker rats (Figure 1). These changes in GLUT4 expression were, in turn, associated 
with alterations in Akt, MAPK, and MEF2 expression and activation that appeared to differ 
between tissue types. 
Insulin-stimulated translocation of GLUT4 to the cell membrane has been shown to be a 
key regulator of glucose uptake [46]. King et al demonstrated that insulin resistance in 
gastrocnemius muscle of obese rats is characterized by an inability to activate Glut4 
translocation following insulin stimulation [47]. Similar findings have been reported by Wai et al 
in hearts of obese Zucker rats who showed that the cardiac expression of GLUT4 in the plasma 
membrane was depressed in the fatty Zucker rat in both the basal and insulin stimulated states 
[48]. The mechanism(s) responsible for the diminished activation of GLUT4 following insulin 
stimulation are not clear however recent data has demonstrated that the activation of protein 
kinase B (Akt) and p38-MAPK may play a pivotal role [34].  
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Herein we demonstrate that insulin resistance is characterized by decreases in the amount 
of phosphorylated (activated) Akt and increases in the amount of phosphorylated p38-MAPK in 
the skeletal muscle and liver of the obese Zucker rat (Figures 2 and 3). Shao and coworkers 
suggested that that decreased insulin-stimulated Akt kinase activity but not MAPK is an 
important component underlying impaired GLUT4 translocation and insulin resistance in skeletal 
muscle of db/db mice [49]. Niu and colleagues observed that GLUT4 activity is regulated by 
insulin in skeletal muscle cells during their maturation into myotubes and that this process is 
related to the ability of insulin to stimulate p38 MAPK [50]. Subsequently Christophe et al found 
that p38 is a strong inducer of GLUT4 expression in cardiac myocyte [9]. Taken together, these 
findings suggest that the regulation of GLUT4 by p38 MAPK appears to differ across various 
tissues and perhaps at different time points within the same tissue.  
PTEN is a dual specificity phosphatase protein involved in tumor suppression and is a 
negative regulator of the Akt signaling pathway. Previous studies have shown that muscle 
specific deletion of PTEN resulted in enhanced insulin stimulated glucose uptake and Akt 
phosphorylation in soleus but not in the extensor digitorum longus  muscle, suggesting that the 
activity of PTEN in glucose regulation is restricted to certain tissues or perhaps dependent on 
other factors [51]. Shen and colleagues recently demonstrated that resistin mediated PTEN 
expression is regulated by p38 MAPK signaling, which may activate target transcription factor 
ATF-2 in human endothelial cells [52]. Herein, we observed that the ratio of phosphorylated to 
total PTEN are increased in the obese Zucker skeletal muscle and liver but decreased in obese 
hearts and kidneys (Figure 4). Whether these findings are directly related to the elevations we see 
if p38 MAPK in the obese Zucker heart and liver is currently unclear.  
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Besides p38 MAPK, it is also thought that ERK1/2 and JNK MAPK may also play a role 
in the development of insulin resistance. Jiro and coworkers demonstrated that JNK1 results in 
substantial protection from obesity-induced insulin resistance [53]. Other work has shown that 
the activation (phosphorylation) of JNK-MAPK inhibits insulin signaling in the rat soleus muscle 
by enhancing the phosphorylation of IRS1 at Ser 307 [54]. Bouzakri et al demonstrated that 
ERK1/2 is phosphorylated to a greater extent in skeletal muscle cells in type 2 diabetic patients 
and that this finding is correlated with phosphorylation of IRS-1 at Ser 636 [55] .Consistent with 
this finding, we observed an elevation in the amount of phosphorylated ERK1/2, JNK -MAPK in 
the skeletal muscle of the obese Zucker rats (Figure 5, 6).  
Myocyte enhancer factor 2A is a member of MEF2 family transcription factors which act 
as muscle-specific DNA binding proteins. Work by Martin et al., in 1998 showed that MEF2 
binding activity is necessary for GLUT4 regulation in skeletal muscle and adipocytes [56]. 
Around this same time Zhao and colleagues found that p38 MAPK regulates MEF2A activity by 
phosphorylating the MEF2A molecule at threonine residues 312 and 319 [57]. More recently, 
work by Morgia and co-workers demonstrated that regulation of GLUT 4 enhancer is dependent 
on MEF2 activity [58]. Consistent with the work of Martin, and our findings of decreased 
GLUT4 expression in the skeletal muscle and hearts of the obese Zucker rat, we also 
demonstrate that the expression of MEF2A was lower in the diabetic heart and skeletal muscle.  
In addition to the potential role that different protein signaling pathways may play in the 
regulation of GLUT4 emerging evidence also suggests that miRNA may also be involved. 
MiRNA are short RNA molecules which act as post-transcriptional regulators by binding to 
complementary mRNA sequence. Recent studies have shown that mir-133a and 223 regulate the 
expression of Glut4 in cardiac myocytes [40].  Other work has shown that mir-133a expression is 
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elevated in the diabetic rabbit heart [59]. In the present study we found that the expression of 
mir-133a is higher while mir-223 expression is lower in the insulin resistant heart. Iai et al 
conducted an extensive study and showed that mir-133a is lowered in skeletal muscle biopsies of 
diabetic humans [60]. We demonstrate a similar finding here where we found that the expression 
of mir-133a, and mir-223 was lower in obese skeletal muscle compared to lean skeletal muscle 
[60]. Whether these changes in miRNA expression are directly related to the changes in GLUT4 
we observe in the obese Zucker skeletal muscle is currently unclear. 
Taken together, our data suggests that GLUT4 regulation appears to be regulated by 
different mechanisms in different tissues. In skeletal muscle, diminished GLUT4 levels appear to 
be correlated with decreases in Akt activation, MEF2A and mir-223 expression. In the liver, 
GLUT4 appears to be regulated, at least in part, through diminished Akt and ERK1/2 MAPK 
activation while in the heart, GLUT4 regulation is tied to decreased ERK1/2 MAPK, JNK-
MAPK, and MEF2A and mir-223 expression. Given these data, it is likely that future studies 
perhaps looking at other molecules are likely needed to further understand the regulation of 
GLUT4 expression in insulin sensitive tissues.   
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CHAPTER 4 
Conclusions 
 
Type 2 diabetes is characterized by insulin resistance which leads to hyperglycemia. 
According to the survey conducted by NIH about 72,000 people died in United States in 2007 
alone due to the effects of diabetes. The main intent of the current study was to investigate how 
insulin resistance affected the expression and activation of signaling molecules thought to play 
key roles in the insulin- stimulated glucose uptake. The following conclusions were drawn from 
the present study: 
 
1. The skeletal muscle, heart and liver of the obese Zucker rat’s exhibits decreased GLUT4 
protein expression. 
2. In skeletal muscle, diminished GLUT4 levels appear to be correlated with decreases in 
Akt activation, MEF2A and mir-223expression.  
3. In the liver, GLUT4 appears to be regulated, at least in part, through diminished Akt and 
ERK1/2 MAPK activation. 
4. In the heart, GLUT4 regulation is tied to decreased ERK1/2 MAPK, JNK-MAPK,    
MEF2A and mir-223 expression. 
5. The kidneys of obese Zucker rat exhibit increases in GLUT4 expression which may be 
related to increased p38 MAPK activation.             
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Future Directions 
 
 Future directions based on this study should focus on examining other molecules thought 
to be involved in the regulation of insulin sensitivity or other in vitro models which may permit 
the testing of how changes in gene expression may directly affect GLUT4 protein expression.  
Other work could also examine the effects of the p38 inhibitor SB-681323 on MEF2 
phosphorylation and how this might affect GLUT mRNA levels.  
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Figure 3. Total levels of GLUT4 are altered in diabetic rats 
 Total levels of GLUT4 in different tissues of lean and obese Zucker male rats at 12weeks of age. 
Results are expressed as arbitrary units for comparison.GAPDH was used as an internal control. 
An asterisk (*) indicates significant differences in obese Zucker rats from the lean Zucker age 
matched controls (P< 0.05). Abbreviations: LM, lean skeletal muscle; OM, obese skeletal 
muscle; LL, lean liver; OL, obese liver; LH, lean heart; OH, obese heart; LK, lean kidney; OK, 
obese kidney. 
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Figure 4. Phosphorylated to total levels of Akt are altered in diabetic rats.  
Phosphorylated to total levels of Akt in different tissues of lean and obese Zucker male rats at 12 
weeks of age. Results are expressed as arbitrary units for comparison. An asterisk (*) indicates 
significant differences in obese Zucker rats from the lean Zucker age matched controls (P< 0.05). 
Abbreviations: LM, lean skeletal muscle; OM, obese skeletal muscle; LL, lean liver; OL, obese 
liver; LH, lean heart; OH, obese heart; LK, lean kidney; OK, obese kidney. 
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Figure 5. Phosphorylated to total levels of p38MAPK are altered in diabetic rats. 
Phosphorylated to total levels s of p38MAPK in different tissues of lean and obese Zucker male 
rats at 12 weeks of age. Results are expressed as arbitrary units for comparison. An asterisk (*) 
indicates significant differences in obese Zucker rats from the lean Zucker age matched controls 
(P< 0.05). Abbreviations: LM, lean skeletal muscle; OM, obese skeletal muscle; LL, lean liver; 
OL, obese liver; LH, lean heart; OH, obese heart; LK, lean kidney; OK, obese kidney. 
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Figure 6. Phosphorylated to total levels of PTEN are altered in diabetic rats.  
Phosphorylated to total levels of PTEN in different tissues of lean and obese Zucker male rats at 
12 weeks of age. Results are expressed as arbitrary units for comparison. An asterisk (*) 
indicates significant differences in obese Zucker rats from the lean Zucker age matched controls 
(P< 0.05). Abbreviations: LM, lean skeletal muscle; OM, obese skeletal muscle; LL, lean liver; 
OL, obese liver; LH, lean heart; OH, obese heart; LK, lean kidney; OK, obese kidney. 
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Figure 7. Phosphorylated to total levels of ERK1/2 are altered in diabetic rats. 
 Phosphorylated to total levels of ERK1/2 in different tissues of lean and obese Zucker male rats 
at 12 weeks of age. Results are expressed as arbitrary units for comparison. An asterisk (*) 
indicates significant differences in obese Zucker rats from the lean Zucker age matched controls 
(P< 0.05). Abbreviations: LM, lean skeletal muscle; OM, obese skeletal muscle; LL, lean liver; 
OL, obese liver; LH, lean heart; OH, obese heart; LK, lean kidney; OK, obese kidney. 
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Figure 8. Phosphorylated to total levels of JNK are altered in diabetic rats.  
Phosphorylated to total levels of JNK in different tissues of lean and obese Zucker male rats at 
12 weeks of age. Results are expressed as arbitrary units for comparison. An asterisk (*) 
indicates significant differences in obese Zucker rats from the lean Zucker age matched controls 
(P< 0.05). Abbreviations: LM, lean skeletal muscle; OM, obese skeletal muscle; LL, lean liver; 
OL, obese liver; LH, lean heart; OH, obese heart; LK, lean kidney; OK, obese kidney. 
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Figure 9. Total levels of MEF2A are altered in diabetic rats.  
Total levels of MEF2A in different tissues of lean and obese Zucker male rats at 12weeks of age. 
Results are expressed as arbitrary units for comparison. GAPDH was used as an internal control. 
An asterisk (*) indicates significant differences in obese Zucker rats from the lean Zucker age 
matched controls (P< 0.05). 
Abbreviations: LM, lean skeletal muscle; OM, obese skeletal muscle; LL, lean liver; OL, obese 
liver; LH, lean heart; OH, obese heart; LK, lean kidney; OK, obese kidney. 
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Figure 10. The expression of mir-1 miRNA is altered in diabetic rats.  
Ratio of expression mir-1 miRNA in different tissues of lean and obese Zucker male rats at 
12weeks of age. An asterisk (*) indicates significant differences in obese Zucker rats from the 
lean Zucker age matched controls (P< 0.05). Abbreviations: LH, lean heart; OH, obese heart; 
LM, lean skeletal muscle; OM, obese skeletal muscle. 
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Figure 11. The expression of mir-133a miRNA is altered in diabetic rats.  
Ratio of expression of mir-133a miRNA in different tissues of lean and obese Zucker male rats at 
12weeks of age. An asterisk (*) indicates significant differences in obese Zucker rats from the 
lean Zucker age matched controls (P< 0.05). Abbreviations: LH, lean heart; OH, obese heart; 
LM, lean skeletal muscle; OM, obese skeletal muscle. 
 
 
 
 
 
39 
 
                                                  
Figure 12. The expression of mir-233 miRNA is altered in diabetic rats.  
Ratio of  expression of mir-233 miRNA in different tissues of lean and obese Zucker male rats at 
12weeks of age. An asterisk (*) indicates significant differences in obese Zucker rats from the 
lean Zucker age matched controls (P< 0.05). Abbreviations: LH, lean heart; OH, obese heart; 
LM, lean skeletal muscle; OM, obese skeletal muscle; LL, lean liver; OL, obese liver. 
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